{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:13:39Z","timestamp":1790813619246,"version":"4.1.0"},"reference-count":141,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"vor","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Dana-Farber Cancer Institute Hale Center for Pancreatic Cancer Research"},{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005979","name":"Lustgarten Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005979","name":"Lustgarten Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005979","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hale Center for Pancreatic Cancer Research"},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001784","name":"Pancreatic Cancer Action Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005979","name":"Lustgarten Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005979","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Cell"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.molcel.2020.04.035","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T10:31:48Z","timestamp":1590489108000},"page":"1070-1085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":219,"title":["Biomarker-Guided Development of DNA Repair Inhibitors"],"prefix":"10.1016","volume":"78","author":[{"given":"James M.","family":"Cleary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey I.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molcel.2020.04.035_bib1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.molcel.2020.04.035_bib2","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-13-1262","article-title":"Efficacy of chemotherapy in BRCA1\/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study","volume":"19","author":"Ang","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib3","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.3095","article-title":"A phase I\/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer","volume":"37","author":"Banerji","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.molcel.2020.04.035_bib4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.molcel.2020.04.035_bib5","doi-asserted-by":"crossref","first-page":"e1000110","DOI":"10.1371\/journal.pgen.1000110","article-title":"Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair","volume":"4","author":"Bennardo","year":"2008","journal-title":"PLoS Genet."},{"key":"10.1016\/j.molcel.2020.04.035_bib6","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.tig.2016.06.007","article-title":"Regulation of single-strand annealing and its role in genome maintenance","volume":"32","author":"Bhargava","year":"2016","journal-title":"Trends Genet."},{"key":"10.1016\/j.molcel.2020.04.035_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/genes7090067","article-title":"DNA polymerase \u03b8: a unique multifunctional end-joining machine","volume":"7","author":"Black","year":"2016","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.molcel.2020.04.035_bib8","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.molcel.2020.04.035_bib9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1101\/gad.14.4.397","article-title":"ATR disruption leads to chromosomal fragmentation and early embryonic lethality","volume":"14","author":"Brown","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.molcel.2020.04.035_bib10","series-title":"Goodman and Gilman\u2019s Phamracological Basis of Therapeutics","author":"Brunton","year":"2011"},{"key":"10.1016\/j.molcel.2020.04.035_bib11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.molcel.2020.04.035_bib12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.molcel.2015.07.029","article-title":"Distinct but concerted roles of ATR, DNA-PK, and Chk1 in countering replication stress during S phase","volume":"59","author":"Buisson","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.molcel.2020.04.035_bib13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.molcel.2019.04.030","article-title":"Topoisomerase II-induced chromosome breakage and translocation is determined by chromosome architecture and transcriptional activity","volume":"75","author":"Canela","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.molcel.2020.04.035_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.15252\/emmm.201809172","article-title":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","volume":"10","author":"Castroviejo-Bermejo","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.molcel.2020.04.035_bib15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nature14184","article-title":"Homologous-recombination-deficient tumours are dependent on Pol\u03b8-mediated repair","volume":"518","author":"Ceccaldi","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.molcel.2020.04.035_bib16","doi-asserted-by":"crossref","first-page":"e1001005","DOI":"10.1371\/journal.pgen.1001005","article-title":"Dual roles for DNA polymerase theta in alternative end-joining repair of double-strand breaks in Drosophila","volume":"6","author":"Chan","year":"2010","journal-title":"PLoS Genet."},{"key":"10.1016\/j.molcel.2020.04.035_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/PO.18.00253","article-title":"Significant tumor response to the poly (ADP-ribose) polymerase inhibitor olaparib in heavily pretreated patient with ovarian carcinosarcoma harboring a Germline RAD51D mutation","author":"Chandran","year":"2018","journal-title":"JCO Precision Oncol."},{"key":"10.1016\/j.molcel.2020.04.035_bib18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrm.2017.48","article-title":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","volume":"18","author":"Chang","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.molcel.2020.04.035_bib19","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1242\/jcs.105353","article-title":"BRCA1-associated exclusion of 53BP1 from DNA damage sites underlies temporal control of DNA repair","volume":"125","author":"Chapman","year":"2012","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.molcel.2020.04.035_bib20","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1093\/nar\/gkn302","article-title":"Mechanistic studies on bleomycin-mediated DNA damage: multiple binding modes can result in double-stranded DNA cleavage","volume":"36","author":"Chen","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41556-019-0442-y","article-title":"TRIP13 regulates DNA repair pathway choice through REV7 conformational change","volume":"22","author":"Clairmont","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.molcel.2020.04.035_bib22","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.molcel.2020.04.035_bib23","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrc3399","article-title":"DNA repair dysregulation from cancer driver to therapeutic target","volume":"12","author":"Curtin","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.molcel.2020.04.035_bib24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/cancers11010119","article-title":"Platinum resistance in ovarian cancer: role of DNA repair","volume":"11","author":"Damia","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.molcel.2020.04.035_bib25","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1093\/nar\/gku088","article-title":"PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage","volume":"42","author":"Das","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.3007","article-title":"First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors","volume":"37","author":"De Bono","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.molcel.2020.04.035_bib27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bcp.2012.03.018","article-title":"The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art","volume":"84","author":"De Vos","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.molcel.2020.04.035_bib28","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41556-018-0140-1","article-title":"Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells","volume":"20","author":"Dev","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.molcel.2020.04.035_bib29","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1200\/JCO.2014.60.4009","article-title":"Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors","volume":"33","author":"Do","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.molcel.2020.04.035_bib30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nrd4553","article-title":"Exploiting replicative stress to treat cancer","volume":"14","author":"Dobbelstein","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molcel.2020.04.035_bib31","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nature21358","article-title":"TIRR regulates 53BP1 by masking its histone methyl-lysine binding function","volume":"543","author":"Dran\u00e9","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.molcel.2020.04.035_bib32","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.molcel.2013.01.001","article-title":"A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice","volume":"49","author":"Escribano-D\u00edaz","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.molcel.2020.04.035_bib33","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1158\/2159-8290.CD-19-0582","article-title":"Combination olaparib and temozolomide in relapsed small-cell lung cancer","volume":"9","author":"Farago","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molcel.2020.04.035_bib34","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41467-020-15315-8","article-title":"Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer","volume":"11","author":"F\u00e4rkkil\u00e4","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molcel.2020.04.035_bib35","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.molcel.2020.04.035_bib36","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.molcel.2020.04.035_bib37","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1182\/bloodadvances.2017015214","article-title":"Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase","volume":"2","author":"Fordham","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.molcel.2020.04.035_bib38","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molcel.2020.04.035_bib39","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40262-017-0587-4","article-title":"PARP inhibitors in the treatment of triple-negative breast cancer","volume":"57","author":"Geenen","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.molcel.2020.04.035_bib40","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ccell.2018.05.008","article-title":"Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality","volume":"33","author":"Gogola","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molcel.2020.04.035_bib41","first-page":"317","volume":"381","author":"Golan","year":"2019","journal-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N. Engl. J. Med."},{"key":"10.1016\/j.molcel.2020.04.035_bib42","first-page":"2391","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med."},{"key":"10.1016\/j.molcel.2020.04.035_bib43","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1093\/nar\/gkp1249","article-title":"Human Rad52 binds and wraps single-stranded DNA and mediates annealing via two hRad52-ssDNA complexes","volume":"38","author":"Grimme","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib44","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41588-019-0390-2","article-title":"Detecting the mutational signature of homologous recombination deficiency in clinical samples","volume":"51","author":"Gulhan","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molcel.2020.04.035_bib45","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.18632\/oncotarget.2158","article-title":"Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970","volume":"5","author":"Hall","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.molcel.2020.04.035_bib46","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41586-018-0670-5","article-title":"DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells","volume":"563","author":"He","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.molcel.2020.04.035_bib47","doi-asserted-by":"crossref","first-page":"8409","DOI":"10.1073\/pnas.1500223112","article-title":"Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer","volume":"112","author":"Henneman","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.molcel.2020.04.035_bib48","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","article-title":"Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids","volume":"8","author":"Hill","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molcel.2020.04.035_bib49","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1126\/science.1073834","article-title":"Biallelic inactivation of BRCA2 in Fanconi anemia","volume":"297","author":"Howlett","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.molcel.2020.04.035_bib50","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.celrep.2016.12.042","article-title":"BRCA1 directs the repair pathway to homologous recombination by promoting 53BP1 dephosphorylation","volume":"18","author":"Isono","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.molcel.2020.04.035_bib51","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/annonc\/mdy076","article-title":"Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors","volume":"29","author":"Italiano","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molcel.2020.04.035_bib52","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-12-0049","article-title":"Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors","volume":"3","author":"Jaspers","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molcel.2020.04.035_bib53","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib54","doi-asserted-by":"crossref","first-page":"17041","DOI":"10.1073\/pnas.1305170110","article-title":"Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance","volume":"110","author":"Johnson","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.molcel.2020.04.035_bib55","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.celrep.2016.10.077","article-title":"CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer","volume":"17","author":"Johnson","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.molcel.2020.04.035_bib56","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.1158\/0008-5472.CAN-13-3369","article-title":"ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses","volume":"74","author":"Joss\u00e9","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib57","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","article-title":"Targeting the ATR\/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models","volume":"23","author":"Kim","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib58","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1158\/0008-5472.CAN-17-3932","article-title":"Mechanistic distinctions between CHK1 and WEE1 inhibition guide the scheduling of triple therapy with gemcitabine","volume":"78","author":"Koh","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-05564-z","article-title":"Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma","volume":"9","author":"Kondrashova","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molcel.2020.04.035_bib60","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-18-1314","article-title":"PARP inhibitors in ovarian cancer: a trailblazing and transformative journey","volume":"24","author":"Konstantinopoulos","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib61","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molcel.2020.04.035_bib62","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.molcel.2020.04.035_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30180-7","article-title":"Randomized phase 2 study of the ATR inhibitor berzosertib in combination with gemcitabine versus gemcitabine alone in platinum resistant high grade serous ovarian cancer (HGSOC)","author":"Konstantinopoulos","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molcel.2020.04.035_bib64","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.molcel.2020.04.035_bib65","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","article-title":"The cytosolic DNA-sensing cGAS-STING pathway in cancer","volume":"10","author":"Kwon","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molcel.2020.04.035_bib66","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.molcel.2020.04.035_bib67","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(18)30009-3","article-title":"Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study","volume":"19","author":"Lee","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molcel.2020.04.035_bib68","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41594-018-0142-5","article-title":"DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs","volume":"25","author":"Li","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.molcel.2020.04.035_bib69","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/1078-0432.CCR-16-1040","article-title":"PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer","volume":"23","author":"Lok","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib70","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.molcel.2020.04.035_bib71","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1158\/1078-0432.CCR-15-0652","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic study of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors","volume":"22","author":"LoRusso","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib72","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-119373","article-title":"CYT01B, a novel RAD51 inhibitor, act synergistically with both targeted and chemotherapeutic anti-cancer agents","volume":"132","author":"Maclay","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.molcel.2020.04.035_bib73","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.currproblcancer.2017.04.002","article-title":"Targeting DNA repair for precision radiotherapy: Balancing the therapeutic ratio","volume":"41","author":"Mahamud","year":"2017","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.molcel.2020.04.035_bib74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.dnarep.2015.04.016","article-title":"CtIP: a DNA damage response protein at the intersection of DNA metabolism","volume":"32","author":"Makharashvili","year":"2015","journal-title":"DNA Repair (Amst.)"},{"key":"10.1016\/j.molcel.2020.04.035_bib75","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nature14157","article-title":"Mammalian polymerase \u03b8 promotes alternative NHEJ and suppresses recombination","volume":"518","author":"Mateos-Gomez","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.molcel.2020.04.035_bib76","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib77","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","article-title":"AZD6738, a novel oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric cancer cells","volume":"16","author":"Min","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.molcel.2020.04.035_bib78","first-page":"1705","volume":"24","author":"Molenaar","year":"2018","journal-title":"IDH1\/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1\/2-mutant inhibitors. Clin. Cancer Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib79","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0021-9258(18)96025-4","article-title":"Effects of arabinonucleotides on ribonucleotide reduction by an enzyme system from rat tumor","volume":"242","author":"Moore","year":"1967","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.molcel.2020.04.035_bib80","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1200\/JCO.2018.78.2425","article-title":"DNA repair deficiency and immunotherapy response","volume":"36","author":"Mouw","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.molcel.2020.04.035_bib81","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-09-2758","article-title":"Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors","volume":"16","author":"Mukhopadhyay","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib82","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib83","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.molcel.2020.04.035_bib84","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1124\/jpet.113.210146","article-title":"Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition","volume":"349","author":"Murai","year":"2014","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.molcel.2020.04.035_bib85","doi-asserted-by":"crossref","first-page":"76534","DOI":"10.18632\/oncotarget.12266","article-title":"Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition","volume":"7","author":"Murai","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.molcel.2020.04.035_bib86","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pharmthera.2019.05.009","article-title":"Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies","volume":"201","author":"Murai","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.molcel.2020.04.035_bib87","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1016\/j.celrep.2018.08.086","article-title":"BRCA1 mutation-specific responses to 53BP1 loss-induced homologous recombination and PARP inhibitor resistance","volume":"24","author":"Nacson","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.molcel.2020.04.035_bib88","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1158\/1078-0432.CCR-14-0571","article-title":"Functional ex\u00a0vivo assay to select homologous recombination\u2013deficient breast tumors for PARP inhibitor treatment","volume":"20","author":"Naipal","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib89","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/cas.12390","article-title":"Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells","volume":"105","author":"Niimi","year":"2014","journal-title":"Cancer Sci."},{"key":"10.1016\/j.molcel.2020.04.035_bib90","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41586-018-0340-7","article-title":"The shieldin complex mediates 53BP1-dependent DNA repair","volume":"560","author":"Noordermeer","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.molcel.2020.04.035_bib91","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.molcel.2020.04.035_bib92","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molcel.2020.04.035_bib93","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1158\/1078-0432.CCR-19-0448","article-title":"The CHK1 inhibitor prexasertib exhibits monotherapy activity in high-grade serous ovarian cancer models and sensitizes to PARP inhibition","volume":"25","author":"Parmar","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib94","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1073\/pnas.1013715108","article-title":"Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells","volume":"108","author":"Patel","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.molcel.2020.04.035_bib95","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/s41467-018-03917-2","article-title":"Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance","volume":"9","author":"Pettitt","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molcel.2020.04.035_bib96","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/bjc.2017.40","article-title":"BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer","volume":"116","author":"Pishvaian","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.molcel.2020.04.035_bib97","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.3094","article-title":"A first-in-human phase I\/II trial of SRA737 (a Chk1 inhibitor) in subjects with advanced cancer","volume":"37","author":"Plummer","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.molcel.2020.04.035_bib98","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/ng.3934","article-title":"A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer","volume":"49","author":"Polak","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molcel.2020.04.035_bib99","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.chembiol.2010.04.012","article-title":"DNA topoisomerases and their poisoning by anticancer and antibacterial drugs","volume":"17","author":"Pommier","year":"2010","journal-title":"Chem. Biol."},{"key":"10.1016\/j.molcel.2020.04.035_bib100","series-title":"Methods in Enzymology","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/bs.mie.2017.03.019","article-title":"DNA fiber analysis: mind the gap!","author":"Quinet","year":"2017"},{"key":"10.1016\/j.molcel.2020.04.035_bib101","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.2008.18.8417","article-title":"Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma","volume":"27","author":"Quinn","year":"2009","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.molcel.2020.04.035_bib102","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-11-2425","article-title":"A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors","volume":"18","author":"Rajan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib103","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00412-017-0658-1","article-title":"Main steps in DNA double-strand break repair: an introduction to homologous recombination and related processes","volume":"127","author":"Ranjha","year":"2018","journal-title":"Chromosoma"},{"key":"10.1016\/j.molcel.2020.04.035_bib104","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature18325","article-title":"Replication fork stability confers chemoresistance in BRCA-deficient cells","volume":"535","author":"Ray Chaudhuri","year":"2016","journal-title":"Nature"},{"issue":"suppl 1","key":"10.1016\/j.molcel.2020.04.035_bib105","article-title":"DNA repair pathways and cisplatin resistance: an intimate relationship","volume":"73","author":"Rocha","year":"2018","journal-title":"Clinics (S\u00e3o Paulo)"},{"key":"10.1016\/j.molcel.2020.04.035_bib106","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/ncb3626","article-title":"EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation","volume":"19","author":"Rondinelli","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.molcel.2020.04.035_bib107","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.molcel.2020.04.035_bib108","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature06633","article-title":"Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers","volume":"451","author":"Sakai","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.molcel.2020.04.035_bib109","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molcel.2020.04.035_bib110","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00280-014-2380-5","article-title":"Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors","volume":"73","author":"Sausville","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.molcel.2020.04.035_bib111","doi-asserted-by":"crossref","first-page":"a012609","DOI":"10.1101\/cshperspect.a012609","article-title":"Nucleotide excision repair in eukaryotes","volume":"5","author":"Sch\u00e4rer","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.molcel.2020.04.035_bib112","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/1878-0261.12573","article-title":"Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells","volume":"13","author":"Schoonen","year":"2019","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.molcel.2020.04.035_bib113","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-13-1391","article-title":"BMN 673, a novel and highly potent PARP1\/2 inhibitor for the treatment of human cancers with DNA repair deficiency","volume":"19","author":"Shen","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib114","doi-asserted-by":"crossref","first-page":"10381","DOI":"10.1128\/MCB.24.23.10381-10389.2004","article-title":"The mouse genomic instability mutation chaos1 is an allele of Polq that exhibits genetic interaction with Atm","volume":"24","author":"Shima","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.molcel.2020.04.035_bib115","first-page":"2018","article-title":"Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation","volume":"2018","author":"Shroff","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.molcel.2020.04.035_bib116","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/ncb1212","article-title":"The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair","volume":"7","author":"S\u00f8rensen","year":"2005","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.molcel.2020.04.035_bib117","doi-asserted-by":"crossref","first-page":"9305","DOI":"10.1128\/MCB.24.21.9305-9316.2004","article-title":"Genetic steps of mammalian homologous repair with distinct mutagenic consequences","volume":"24","author":"Stark","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.molcel.2020.04.035_bib118","doi-asserted-by":"crossref","first-page":"v159","DOI":"10.1093\/annonc\/mdz244.013","article-title":"Updated results of the PARP1\/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumor","volume":"30","author":"Stradella","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molcel.2020.04.035_bib119","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1093\/nar\/gkq1241","article-title":"Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate","volume":"39","author":"Str\u00f6m","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molcel.2020.04.035_bib121","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molcel.2020.04.035_bib122","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1158\/1078-0432.CCR-19-1089","article-title":"Targeting topoisomerase I in the era of precision medicine","volume":"25","author":"Thomas","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib123","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","article-title":"Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors","volume":"36","author":"Thomas","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.molcel.2020.04.035_bib124","doi-asserted-by":"crossref","first-page":"37","DOI":"10.15252\/embj.201899543","article-title":"FAM35A associates with REV7 and modulates DNA damage responses of normal and BRCA1-defective cells","volume":"37","author":"Tomida","year":"2018","journal-title":"EMBO J."},{"key":"10.1016\/j.molcel.2020.04.035_bib125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/genes10010025","article-title":"Targeting DNA double-strand break repair pathways to improve radiotherapy response","volume":"10","author":"Toulany","year":"2019","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.molcel.2020.04.035_bib126","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3390\/cancers10070240","article-title":"Nucleobase and nucleoside analogues: resistance and re-sensitisation at the level of pharmacokinetics, pharmacodynamics and metabolism","volume":"10","author":"Tsesmetzis","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.molcel.2020.04.035_bib127","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1158\/0008-5472.CAN-18-3631","article-title":"Exploiting DNA replication stress for cancer treatment","volume":"79","author":"Ubhi","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib128","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molcel.2020.04.035_bib129","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","article-title":"Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer","volume":"5","author":"Vinayak","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.molcel.2020.04.035_bib130","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/1535-7163.MCT-18-0010","article-title":"The ATR inhibitor AZD6738 synergizes with gemcitabine in\u00a0vitro and in\u00a0vivo to induce pancreatic ductal adenocarcinoma regression","volume":"17","author":"Wallez","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.molcel.2020.04.035_bib131","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.18632\/oncotarget.4919","article-title":"The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and E\u03bc-MYC driven B-cell lymphoma","volume":"7","author":"Walton","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.molcel.2020.04.035_bib132","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.1158\/1078-0432.CCR-17-0544","article-title":"Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer","volume":"23","author":"Weigelt","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib133","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.dnarep.2016.05.003","article-title":"DNA polymerase \u03b8 (POLQ), double-strand break repair, and cancer","volume":"44","author":"Wood","year":"2016","journal-title":"DNA Repair (Amst.)"},{"key":"10.1016\/j.molcel.2020.04.035_bib134","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1158\/1535-7163.MCT-13-0404","article-title":"Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor","volume":"12","author":"Xiao","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.molcel.2020.04.035_bib135","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1101\/gad.10.19.2401","article-title":"Dual roles of ATM in the cellular response to radiation and in cell growth control","volume":"10","author":"Xu","year":"1996","journal-title":"Genes Dev."},{"key":"10.1016\/j.molcel.2020.04.035_bib136","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature14328","article-title":"REV7 counteracts DNA double-strand break resection and affects PARP inhibition","volume":"521","author":"Xu","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.molcel.2020.04.035_bib137","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1101\/gad.290957.116","article-title":"ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells","volume":"31","author":"Yazinski","year":"2017","journal-title":"Genes Dev."},{"key":"10.1016\/j.molcel.2020.04.035_bib138","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/0008-5472.CAN-18-2480","article-title":"Differential activity of ATR and WEE1 inhibitors in a highly sensitive subpopulation of DLBCL linked to replication stress","volume":"79","author":"Young","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib139","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1083\/jcb.201406099","article-title":"Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells","volume":"208","author":"Zellweger","year":"2015","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.molcel.2020.04.035_bib140","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1093\/nar\/gkq1304","article-title":"Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells","volume":"39","author":"Zhang","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.molcel.2020.04.035_bib141","doi-asserted-by":"crossref","first-page":"15030","DOI":"10.1073\/pnas.1205943109","article-title":"Putative DNA\/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents","volume":"109","author":"Zoppoli","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Molecular Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109727652030277X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109727652030277X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:31:44Z","timestamp":1761093104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109727652030277X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":141,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S109727652030277X"],"URL":"https:\/\/doi.org\/10.1016\/j.molcel.2020.04.035","relation":{},"ISSN":["1097-2765"],"issn-type":[{"value":"1097-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarker-Guided Development of DNA Repair Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Molecular Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molcel.2020.04.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}